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Abstract: Hematopoietic stem cell transplantation
cure  currently  available  for  patients  with  thalassemia  and  sickle  cell  anemia.    Results  of 
transplant in thalassemia  and in sickle cell anemia  have steadily improved over the last two 
decades due to improvements in preventive strategies, and effective control of transplant
related complications. From 2004 through  2009,  145 consecutive patients 
and  sickle  cell  anemia,  ethnically  heterogeneous  from  Mediterranean  and  Middle  East 
countries, were given HSCT in the International Center for Transplantation in Thalassemia 
and  Sickle  Cella  Anemia  in  Rome.  This  experience  is  characterized  by  two  pecu
patients were ethnically very heterogeneous and the vast majority of these patients were not 
regularly transfesed/chelated and therefore were highly sensitized due to RBC transfusions 
without leukodepletion filters. Consequently, they could have
a  result  of  sensitization  to  HLA  antigens.  The  Rome  experience  of  SCT  in  patients  with 
thalassemia  and  sickle  cell  anemia
importantly showed the reproducibility of these 
Thalassemia:  The  pathophysiology  of 
thalassemia relates to  a quantifiable  deficiency  of 
functional -globin, which leads to an imbalanced 
globin chain production and an excess of 
chains
1,2.  The  latter  are  not  able  to  form  viable 
tetramers  and  instead  precipitate  in  the  red  cell 
precursors  forming  inclusion  bodies  that  cause 
mechanical damage and the premature destruction 
of red cell precursors in the bone marrow leading to 
ineffective erythropoiesis. The red cells that survive 
to reach the peripheral circulation are prematurely 
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Hematopoietic stem cell transplantation (HSCT) still remains the only definitive 
cure  currently  available  for  patients  with  thalassemia  and  sickle  cell  anemia.    Results  of 
halassemia  and in sickle cell anemia  have steadily improved over the last two 
decades due to improvements in preventive strategies, and effective control of transplant
From 2004 through  2009,  145 consecutive patients 
ethnically  heterogeneous  from  Mediterranean  and  Middle  East 
countries, were given HSCT in the International Center for Transplantation in Thalassemia 
and  Sickle  Cella  Anemia  in  Rome.  This  experience  is  characterized  by  two  pecu
patients were ethnically very heterogeneous and the vast majority of these patients were not 
regularly transfesed/chelated and therefore were highly sensitized due to RBC transfusions 
without leukodepletion filters. Consequently, they could have a high risk of graft rejection as 
a  result  of  sensitization  to  HLA  antigens.  The  Rome  experience  of  SCT  in  patients  with 
and  sickle  cell  anemia confirmed  the  results  obtained  in  Pesaro,  and  most 
importantly showed the reproducibility of these results in other centers. 
The  pathophysiology  of  -
thalassemia relates to  a quantifiable  deficiency  of 
globin, which leads to an imbalanced 
chain production and an excess of α globin 
.  The  latter  are  not  able  to  form  viable 
tetramers  and  instead  precipitate  in  the  red  cell 
precursors  forming  inclusion  bodies  that  cause 
mechanical damage and the premature destruction 
of red cell precursors in the bone marrow leading to 
ropoiesis. The red cells that survive 
to reach the peripheral circulation are prematurely 
destroyed in the spleen, which becomes enlarged, 
eventually leading to hypersplenism. Thus, anemia 
in   thalassemia  results  from  a  combination  of 
ineffective erythropoiesis, peripheral hemolysis and 
an  overall  reduction  in  hemoglobin  synthesis 
leading to intense proliferation and expansion of the 
bone marrow with the resulting skeletal deformities.
Currently  recommended  non
is  available  in  most  count
transfusions to maintain hemoglobin levels between 
9 and 10g/dL together with chelation therapy aimed 
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(HSCT) still remains the only definitive 
cure  currently  available  for  patients  with  thalassemia  and  sickle  cell  anemia.    Results  of 
halassemia  and in sickle cell anemia  have steadily improved over the last two 
decades due to improvements in preventive strategies, and effective control of transplant-
From 2004 through  2009,  145 consecutive patients with thalassemia 
ethnically  heterogeneous  from  Mediterranean  and  Middle  East 
countries, were given HSCT in the International Center for Transplantation in Thalassemia 
and  Sickle  Cella  Anemia  in  Rome.  This  experience  is  characterized  by  two  peculiarities: 
patients were ethnically very heterogeneous and the vast majority of these patients were not 
regularly transfesed/chelated and therefore were highly sensitized due to RBC transfusions 
a high risk of graft rejection as 
a  result  of  sensitization  to  HLA  antigens.  The  Rome  experience  of  SCT  in  patients  with 
confirmed  the  results  obtained  in  Pesaro,  and  most 
destroyed in the spleen, which becomes enlarged, 
eventually leading to hypersplenism. Thus, anemia 
thalassemia  results  from  a  combination  of 
oiesis, peripheral hemolysis and 
an  overall  reduction  in  hemoglobin  synthesis 
leading to intense proliferation and expansion of the 
bone marrow with the resulting skeletal deformities.
Currently  recommended  non-transplant  therapy 
is  available  in  most  countries  and  consists  of  
transfusions to maintain hemoglobin levels between 
9 and 10g/dL together with chelation therapy aimed Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
at preventing iron accumulation as a consequence of 
the  transfusion  therapy.  Future  treatment  of  the 
thalassemic patient may be easier and improved if 
orally administered iron chelators become available. 
Two potentially useful oral chelators (Deferasirox 
and  Deferiprone)  are  now  available,  but  their 
efficacy compared to desferrioxamine in the long-
term has not yet been determined. 
Bone  Marrow  Transplantation  in  -
Thalassemia: The purpose of allogeneic HCT for 
hemoglobinopathies is to correct the basic genetic 
defect  by  repleting  genes  essential  for  normal 
hematopoiesis  through  allogeneic  stem  cells  as 
vectors  following  conditioning  to  overcome  the 
immunological barrier.
Therefore  allogeneic  HCT  in  these  diseases 
could  be  considered  as  allogeneic  stem  cell  gene 
therapy.  It  is  a  form  of  gene  therapy  that  uses 
allogeneic stem cells as vectors for genes essential 
for  normal  hematopoiesis.  Eventually,  the  vector 
may well be autologous stem cells transformed by 
the  insertion  of  normal  genes  but  there  is  no 
indication  that  this  approach  will  be  a  clinical 
option in the foreseeable future. 
Preparatory regimens for HCT of patients with 
diseases  other  than  aplastic  anemia  must  achieve 
two  objectives.  One  is  elimination  of  the 
hemopoietic marrow and the other is to create  a 
tolerant  environment  that  will  allow  the 
transplanted  marrow to  survive  and  thrive.  Total 
body irradiation  (TBI) can  accomplish  both  these 
objectives, but there are many reasons to avoid the 
use of this marrow-ablative modality. These include 
the known growth-retarding effects of TBI in young 
children  and  the  increased  risk  of  secondary 
malignancies, which has been reported in patients 
treated  for  leukemia
3,  lymphoma  and  aplastic 
anemia
4,5.  These  hazards  are  particularly 
objectionable in very young patients with potential 
for a long life span. The risk of these toxicities has 
not yet been fully explored for cytotoxic regimens 
that  do  not  involve  TBI.  There  is  a  considerable 
body of experience with the use of busulfan (BU) 
and  its  derivatives  in  ablating marrow in  patients 
undergoing HCT for the treatment of non-malignant 
conditions such as the Wiskott-Aldrich syndrome
6,7
and  inborn  errors  of  metabolism
8. 
Cyclophosphamide  (CY)  is  an  agent  that  is  well 
established  as  providing  immunosuppression 
adequate for allogeneic engraftment of patients with 
aplastic  anemia
9,10.  Experience  in  the  use  of 
chemotherapy-only  transplant  regimens  for  the 
treatment  of  malignancy
11-16 has  been  pivotal  in 
developing regimens appropriate for the treatment 
of thalassemia by transplantation.
BU  is  an  alkylating  agent  with  exquisite 
specificity for the most primitive precursors of the 
myeloid-erythroid axis. Clinical experience with the 
use of BU in very high doses was delayed due to the 
lack  of  an  acceptable  preparation  suitable  for 
intravenous  use.  Santos  et al.  reported  the  first 
clinical trials of very high-dose BU in the context of 
BMT
13.  In  these  studies,  patients  with  acute 
myeloid  leukemia  (AML)  received  allogeneic 
marrow  transplants  after  immunosuppression  with 
CY (200mg/kg over 4 days), and oral BU (16mg/kg 
over  4  days)  was  administered  as  additional 
antitumor  therapy.  Early  results  with  this  therapy 
were  encouraging,  and  in  successful  attempts  to 
reduce early transplant-related toxicity, Tutschka et
al. reduced the CY dose to 120mg/kg over 2 days 
17.
Further,  CY  has  been  a  component  of  most 
conditioning  regimens  for  transplanting  patients 
with  hematologic  malignancies.  Santos  et al. 
reported on its use in high doses (200mg/kg over 4 
days)  as  the  sole  antitumor  agent  in  patients 
receiving  allogeneic  transplants  for  leukemia  and 
demonstrated  that  it  was  sufficiently 
immunosuppressive to  permit  sustained allogeneic 
engraftment
11.  Also,  CY  is  most  commonly 
employed  for  the  treatment  of  lymphoid 
malignancies and solid tumors, and it has been used 
as a component of combination chemotherapy for 
the treatment of acute leukemia. It is not considered 
a  highly  effective  agent  against  myeloid 
malignancies, although single drug studies are not 
available in this context. The dose-limiting toxicity 
of CY is to the heart and not to the marrow. Mice, 
monkeys  and  humans  recover  hematopoiesis 
promptly after the highest doses of CY because CY 
does not eliminate HSCs. Therefore CY alone is not 
an appropriate conditioning modality for BMT for 
the  treatment  of  thalassemia  because  the 
thalassemic marrow would recover rapidly. On the 
other  hand,  BU  is  an  agent  which  has a  good 
possibility  of  eradicating  a  diseased  erythron  but 
when  used  alone  is  not  likely  to  be  sufficiently 
immunosuppressive to  permit  sustained allogeneic 
engraftment. In summary, a combination of BU and 
CY  can  eradicate  the  thalassemia  and  facilitate 
sustained allogeneic engraftment. 
Most patients undergoing transplantation for the 
treatment  of  thalassemia  have  been  transfused 
repeatedly.  This  lead  to  sensitization  to  HLA 
antigens  therefore  could  increase  the  risk  of 
rejection  as  it  has  been  demonstrated  in  patients 
with aplastic anemia
18, 19.Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
The  treatment  of  patients  after  graft  rejection 
will  differ  depending  on  whether  the  rejection  is 
accompanied  by  regeneration  of  host  type 
hematopoiesis or by marrow aplasia. 
Preparatory  regimens  capable  of  eradicating  a 
diseased  marrow  and  facilitating  persistent 
engraftment  are  necessarily  toxic,  and  the 
consequences  of  successful  allogeneic  marrow 
engraftment include acute and chronic graft-vs.-host 
disease (GVHD), syndromes associated with severe 
immune  incompetence.  Regimen-related  toxicity 
has been well described in patients treated by BMT 
for  hematologic  malignancies
20,21.  The  lungs  and 
liver are the organs most at risk for toxicity induced 
by TBI and BU while the heart is the main site of 
CY-induced  damage.  Increasing  patient  age, 
previous  exposure  to  cytotoxic  agents  and  the 
presence of latent viruses such as hepatitis C and 
cytomegalovirus  adversely  influence  these 
toxicities. Patients transplanted for the treatment of 
thalassemia  derive  benefit  from  the  fact  they  are 
usually  young  and  without  prior  exposure  to 
cytotoxic  agents.  However,  because  of  previous 
intensive transfusion therapy they will have a high 
probability  of  carrying  harmful  viruses  and  have 
organ damage induced by extreme iron overload.
Risk Factors  and  Risk Classes:  Analysis  of  the 
influence  of  pretransplant  characteristics  on  the 
outcome  of  transplantation  was  conducted  in  222 
patients aged less than 17 years who were all treated 
with exactly the same regimen
22, 23.  In multivariate 
analysis  hepatomegaly  more  than  2  cm,  portal 
fibrosis  and  irregular  chelation  history  were 
associated with a significantly reduced probability 
of  survival.  The  quality  of  chelation  was 
characterized as regular when deferoxamine therapy 
was initiated no later than 18 months after the first 
transfusion and administered subcutaneously for 8–
10  h continuously  for  at least 5 days each  week. 
Any  deviation  from  this  regimen  was  defined  as 
irregular chelation. On the basis of these risk factors 
patients  were  categorized  into  three  risk  classes. 
Class  1  patients  had  none  of  these  adverse  risk 
factors,  class  3  patients had all  three and  class 2 
patients had one or two adverse risk factors.
The  Use  of  Unrelated  Donors:  Results  of  HCT 
from  unrelated  donors  for  the  treatment  of 
malignant disease have improved steadily,  mainly 
due to the introduction of high-resolution molecular 
techniques  for  histocompatibility  testing  and 
improvements in the management of post-transplant 
complications. These results have stimulated the use 
of HCT from unrelated donors for the treatment of 
hemoglobinopathies. The Italian cooperative group 
for  bone  marrow  transplantation  (Cagliari,  Pavia, 
Pesaro  and  others)    has  recently  reported  results 
obtained  in  32  thalassemic  patients  (aged  2-28 
years)  who received bone marrow from unrelated 
donors selected for similarity with the recipients for 
extended  HLA  haplo-types
24.  The  probability  of 
thalassemia-free  survival  was  66%  for  the  entire 
group  and  the  mortality  from  causes  other  than 
rejection was 25%. Although the difference was not 
significant,  five  of  the  six  patients  who  died 
belonged  to  class 3.  The incidences  of  grade 2-4 
acute and of chronic GVHD were 41% and 25%, 
respectively.  Patients  who  shared  at  least  one 
extended  haplotype  had  less  acute  or  chronic 
GVHD and better survival. 
Recently this group has reported data on 27 adult 
thalassemia patients (aged 17-37 years) transplanted 
from  unrelated donors selected by high resolution 
HLA  molecular  typing
25.  The  probability  of 
survival,  thalassemia-free  survival,  transplant-
related  mortality  and  rejection  were  70  %,  70%, 
30% and  4% respectively. The incidence of grade 
II-IV acute and chronic GVHD was 37% and 27%, 
respectively. Although limited these data show that 
unrelated marrow transplatation not only in younger 
patients but also in adult patients from well-selected 
donors  may  offer  a  success  rate  similar  to  those 
obtained  from  HLA-identical  sibling 
transplantation. 
Unrelated  Cord  Blood  Transplantation: 
Hematopoietic  stem  cell  transplantation  from  an 
unrelated cord blood (UCB) donor is, now, standard 
practice  for  the  treatment  of  hematological 
malignancies. The number of UCB transplants has 
increased dramatically, because several studies have 
demonstrated  that  results  from  HLA-mismatched 
UCB  transplants  were  comparable  to  those  from 
HLA-matched unrelated bone marrow transplants in 
children
26.  Advantages  such  as  faster  availability, 
tolerance  of  1-2  HLA  mismatches,  and  low 
incidence  of  acute  GVHD made UCB transplants 
attractive for  patients  with some  non  malignant 
diseases
27. Five patients (aged 2.3- 11.4 years) with 
-thalassemia  major  were  given  unrelated  cord 
blood transplantation in Taiwan
28. Cord blood units 
were  mismatched  for  2-loci  in  2  recipient/donor 
pairs, and the remaining 3 pairs had a mismatched 
at 1 locus. Patients were given BU14 mg/kg, CY 
200 mg/kg and antithymocyte globulin 30 mg/kg as 
conditioning and CSP and  methylprednisolone as 
GVHD  prophylaxis.  Nucleated  cell  dose    ranged Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
from  3.25  to  11.8  x  10
7/kg.  All  patients  had 
sustained  engraftment  with  complete  donor 
chimerism.  Three  patients  had  grade  II-III  acute 
GVHD responsive to steroid treatment. These data 
are  very encouraging and show that  patients who 
need  transplantation  and  do  not  have  a  suitable 
either  related  or  unrelated  matched  donor  can 
benefit from unrelated cord blood transplatation .
Pesaro  Experience  in  Patients  With 
Thalassemia:  Beetween  May  1985  and  
December 2003, 498 patients <17 years of age had 
received HLA-identical transplants using regimens 
containing BU 14mg/kg and CY 200mg/kg. There 
were 150 class 1 patients, 315 class 2 patients and 
33  class  3  patients.  The  probabilities  of  survival, 
thalassemia-free  survival,  rejection  and  non-
rejection mortality for class 1 patients were 90%, 
87%,  3%  and  10%,  respectively,  and  for  class  2 
patients  they  were  87%,  85%,  3%  and  13%, 
respectively 
Between  October  1985  and  August  2007  five 
hundred and fifteen class 1 and class 2 patients with 
median age of 7 years (range 1 to 16 years) were 
given  bone  marrow  transplantation  following 
conditioning  with  Bu  3,5  mg/kg/day  for  4 
consecutive  days  and  CY  50  mg/kg/day  for 
subsequent 4  days. Since  2003  patients  aged less 
than 4 years were also given thiotepa 10 mg/kg/day 
in  addition  to  BUCY.  Four  hundred  and  seventy 
eight of these patients were given transplant at the 
Hospital  of  Pesaro
22,29 and  37  patients  received 
BMT at the  University Policlinic of Tor Vergata. 
Graft- versus-host disease prophylaxis consisted of 
cyclosporine  (CSA)  and  low-dose 
methylprednisolone  (MP)  and  since  June  2001 
CSA,  MP  and  a  modified  ‘‘short  course’’  of 
methotrexate (MTX). 
When class 3 younger patients (age <17 years) 
treated with the same conditioning as class 1 and 
class 2 patients (BU14 mg/kg and CY200 mg/kg), 
showed  a  low  probability  of  thalassemia- free 
survival  (53%)  and  a  higher  probability  of  non-
rejection transplant related mortality (39%) 
30.  In an 
attempt to improve results in class 3 patients, new 
treatment  regimens  were  devised  using  BU 
14mg/kg  and  lower  doses  of  CY  (160  or 
120mg/kg).  These  regimens  improved  the 
probability of survival in class 3 younger (age<17 
years)  patients  from  53%  to  79%,  but  were 
associated with an increase of rejection probability 
from  7%  to  30%,  probably  due  to  inadequate 
immunosuppression  and  failure  to  eradicate  the 
massive erythroid hyperplasia characteristic of these 
patients
29-31.
In  April  1997  a  new  preparative  regimen 
(Protocol 26) was adopted for class 3 patients <17 
years of age in an attempt to decrease the higher 
rejection rate through reducing erythroid expansion 
and  increasing  immunosuppression  over  time  to 
avoid  unacceptable  drug  toxicity  during 
conditioning regimen
32.  Protocol 26 was devised on 
the assumption that preparation with BU 14mg/kg 
and  CY  160mg/kg  was  inadequate  to  eradicate 
thalassemic hematopoiesis in  class 3 patients <17 
years  of  age.  Patients  were  given  azathioprine 
3mg/kg and hydroxyurea 30mg/kg daily from day -
45 from the transplant, fludarabine 20mg/m2 from 
day  -17  through  day-13,  followed  by  the 
administration of BU 14mg/kg total dose and CY 
160mg/kg  total  dose.  Graf-tversus-host  disease 
prophylaxis  consisted  of  CSA,  low-dose 
methylprednisolone and a modified ‘‘short course’’ 
of MTX. As reported in Table 1, the probabilities 
of survival, thalassemia-free survival, rejection and 
non-rejection mortality in 33 such patients treated 
with  Protocol  26  were  93%,  85%,  8%  and  6%, 
respectively 
32. 
Adult thalassemia patients have more advanced 
disease  with  both  disease  and  treatment  related 
organ  complications  mainly  due  to  prolonged 
exposure  to  iron  overload.  From  November  1988 
through September 1996, 107 patients older than 16 
years  received  transplants  from  matched  donors. 
The median age for this population was 20 years 
(range  17-35  years).  The  probability  of  survival, 
thalassemia-free  survival,  rejection  and  non-
rejection  mortality  for  the  entire  group  of  these 
patients  were  66%, 62%,  4%  and  37% 
respectively
33, 34. 
From April 1997 all adult patients were prepared 
for transplantation according to Protocol 26 with the 
only difference that the dose of cyclophosphamide 
was reduced to 90 mg/kg total dose. The probability 
of survival, thalassemia-free survival, rejection and 
non-rejection  mortality  in  15  high  risk  group 
patients  were  65%,  65%,  7%  and  28% 
respectively
35. 
The Experience of the International Center for 
Transplantation in Thalassemia and Sickle Cella 
Anemia in Roma: This experience is characterized 
by two peculiarities: patients were ethnically very 
heterogeneous  and  the  vast  majority  of  these 
patients were not regularly transfused/chelated and 
therefore  were  highly  sensitized  due  to  RBC 
transfusions without leukodepletion filters. Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Table 1. Country of origin of 145 patients transplanted at Roma 
Center from 2004 through  2009.
Country of origin N° of patients
AFGHANISTAN 2
ALBANIA 3
ARGENTINA 4
BAHREIN 3
BULGARIA 1
CANADA 1
CYPRUS 2
EGYPT 10
IRAQ 32
ITALIA 2
KUWAIT 31
LEBANON 25
MADAGASCAR 1
MALDIVES 10
NEPAL 1
PAKISTAN 3
PALESTINE 7
QATAR 1
ROMANIA 2
RUSSIA 1
SYRIA 2
USA 1
TOTAL 145
Therefore these patients  could have a higher risk of 
graft rejection as a result of sensitization to HLA 
antigens.    From  June  2004  through  September  
2009,  one  hundred  and  forty  five  consecutively 
patients (84 male and 61 female)   with thalassemia 
and  sickle  cell  anemia were  given  BMT  at  the 
Roma  Center.    Table  1 shows  the  geographic 
distribution of  the patients. 
RESULTS 
HLA  Identical    Patients:  Class  1  and  class  2 
patients  under  4  years  of  age  were  given 
BU14CY200  and  thiotepa 10  mg/kg  total  dose, 
while  patients  ≥  4  years  of  age  received 
BU14CY200  as  preparatory  regimen.  Prophylaxis 
against  GVHD  consisted  of  CSP,  low  dose  of 
methylprednisolone  and    a  short  course  of MTX. 
Class 3 patients were prepared for BMT according 
to Protocol 26. Since June 2006, all patients were 
given targeted dose of intravenous Busilvex instead 
of oral Busulfan. The treatment  protocols in use are  
shown in Table 2.
The  preliminary  data  relative  to  106  HLA 
identical    patients  shows  that  the  probabilities  of 
survival,  thalassemia-free  survival,  rejection  and 
non-rejection  mortality  in    class  1  patients    (20 
patients) were  95%, 90%, 5% and 5% respectively.  
38  patients  in  class  2  showed  a  survival, 
thalassemia-free  survival,  rejection  and  non-
rejection  mortality  of  89%,  84%,  12%  and  5% 
respectively. In 48 class 3 patients  we observed a 
survival,  thalassemia-free  survival,  rejection  and 
non-rejection mortality of 87%, 81% 11% and 9%  
The  Rome  experience  in  HLA  identical  patients 
confirmed the results obtained in Pesaro.
Second  Transplant    in  Patients  With 
Thalassemia  Recurrence:  There  is  a  substantial 
incidence  of  graft  failure  in  patients  with 
thalassemia  after  myeloablative  conditioning 
regimens especially in class 3 patients in whom its 
incidence  could be  as  high  as  8-38.5%.  Most 
patients  with  graft  failure  have  recurrence  of 
thalassemic marrow.
We have  recently published data on 16  patients 
with thalassemia recurrence following rejection of 
the first graft who were given second transplants. 
The  median  of    age    was  9  years  (range,  4-20). 
These patients were given second transplant using 
BM (n=7) or PBSC (n=9) after preparation with a 
new  treatment  protocol.  All  but  two  patients 
received  stem  cells  from  the  same  donor.  The 
median  interval  between  two  transplants  was  28 
months (range, 8-204). The sustained engraftment 
rate was high (94%) with only one patient having 
primary  graft  failure.  The  probability  of  overall 
survival, event-free survival, TRM and graft failure 
were 79, 79, 16 and 6%, respectively. There were 
three  transplant-related  deaths.  This  intensified 
treatment  protocol  was  well  tolerated  with  no 
significant increase in toxicity
36.
Haploidentical  Hematopoietic  Stem  Cell 
Transplantation  from  a Mismatched  Family 
Member  in  Patient  With  -Thalassemia: 
Approximately  25%  to  30%  of  patients  with 
thalassemia  could  have  an  HLA  matched  related 
donor. As HSCT is the only cure for thalassemia 
there  is  need  to  develop  alternative  stem  cells 
donations.  Our  past  experience  with  BMT  from 
alternative  donors  for  29  patients  with  -
thalassemia  major  who  received  phenotypically 
matched grafts or haploidentical grafts mismatched 
for one, two, or three antigens was characterized by 
higher graft failure (55%), and low thalassemia-free 
survival  (21%)
37.  Haploidentical  hematopoietic 
stem cell transplantation from a mismatched family 
member (HaploHSCT) donor offers an alternative Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Table 2. Current treatment protocols.
Risk Classes Pre Conditioning Conditioning GvHD prophylaxis
Class 1 & Class 2 > 4 yrs none Pc 6
*Bu14 CY200 CSA/MP/sMTX
Class 1 & Class 2 ≤ 4 yrs none Pc 6.1
Bu16 TT10CY200 CSA/MP/sMTX
Class 3 <17 yrs
before February 2007
d-35 -11: AZ,HU
d-16 -11: Flu 100
G-CSF, DFO
Pc 26
Bu14 CY160 CSA/CY/MP/sMTX
Class 3 <17 yrs
Since  February 2007
d-35 -11: AZ,HU
d-16 -11: Flu 150
G-CSF, DFO
Pc 26 modified
i.v.Bu TT10CY160 CSA/CY/MP/sMTX
Adults (age > 17 yrs)
Class 1-3. since 2/2007
d-35 -11: AZ,HU
d-16 -11: Flu 150
G-CSF, DFO
Pc 26 modified
i.v.Bu TT10CY90 CSA/CY/MP/sMTX
Bu=Busulfan - *Since June 2006 all patients receive i.v. Busulfan (Busilvex); CY =Cyclophosphamide; MP= methylprednisolone; 
CSA=Cyclosporine; MTX= methotrexate; TT=thiotepa; Flu=Fludarbine; AZ=Azathioprine; Hu=hydroxyurea; DFO=deferoxamine,
G-CSF=granulocyte colony-stimulating factor
option  for  patients  who lack an  human leukocyte 
antigen (HLA)-matched donor. The main obstacles 
are graft rejection, delayed immune reconstitution, 
graft-versus-host  disease  (GvHD)  and  higher 
frequency  of  opportunistic  infections.  Assuming 
that  the  immunotollerance  established  during  the 
pregnancy might help to bypass the HLA disparity
we started a transplant program of haploidentical T-
cell  depleted  HCT  from  mother  to  child  for 
thalassemia in 2002. Feto-maternal microchimerism 
suggests immunological tolerance between mother 
and  fetus.  Thus,  we  performed  primary 
hematopoietic  stem-cell  transplantation  (HSCT) 
from  mismatched  mother  to  thalassemic  patient 
without an HLA-identical donor. 
We have recently published data relative to 22  
patients with thalassemia major
38.
These patients  were conditioned with 60 mg/kg 
hydroxyurea and 3 mg/kg azathioprine from day -59 
to -11, 30 mg/m(2) fludarabine from day -17 to -11, 
14  mg/kg  busulfan  starting  on  day  -10,  and  200 
mg/kg cyclophosphamide, 10 mg/kg Thiotepa, and 
anti-thymocyte globulin daily from day -5 to -2. 14 
patients received CD34(+) mobilized peripheral and 
bone  marrow  progenitor  cells;  eight  patients 
received marrow graft selected PBSC CD34(+) and 
BM CD3/CD19 depleted . T-cell dose was adjusted 
to 2 x 10(5)/kg by fresh marrow cell add-back at the 
time  of  transplant.  Both  groups  received 
cyclosporine for graft versus host disease (GVHD) 
prophylaxis  for  two  months  post  transplant.  Two 
patients  died  (cerebral  EBV  lymphoma  or  CMV 
pneumonia), six patients reject their grafts, and 14 
showed full chimerism with functioning grafts at a 
median  follow-up  of  40  months.  None  of  the  14 
patients  who  showed  full  chimerism  developed 
acute or chronic GVHD.  In a part of these patients 
we  performed  an  immunological  study  to 
investigate  immunological  tolerance  and  immune 
reconstitution post transplantation.
In haploidentical hematopoietic transplantation, 
donor-versus-recipient  NK  cell  alloreactivity 
derives from a mismatch between donor NK clones 
bearing  inhibitory  Killer  Cell  Ig-like  Receptors 
(KIRs)  for  self  HLA  class  I  molecules  and  their 
HLA  class  I  ligands  (KIR  ligands)  on  recipient 
cells.  The  mechanism  whereby  alloreactive  NK 
cells exert their benefits in transplantation has been
elucidated. The infusion of alloreactive NK cells 1) 
ablates recipient T cells which reject the graft, and 
2)  ablates  recipient  dendritic  cells  (DCs)  which 
trigger GvHD, thus protecting from GvHD. NK cell 
alloreactivity also  boosts very rapid  rebuilding of 
donor  adaptive  immunity  to  infections.  Immuno 
haematological  reconstitution  was  therefore 
analysed in some patients after HLA-haploidentical 
transplant
39. T and B cell depletion was carried out 
with  CD34+ coated magnetic  microbeads and the 
CliniMACS  device  (Miltenyi  Biotec©)  from 
peripheral blood and bone marrow of donors (the 
mothers) and resulted in grafts consisting of stem 
cells and effector cells (NK cells, monocytes) with 
the  addition  of  bone  marrow  mononuclear  cells 
(BMMNCs 3 x 10
5/kg of the recipient). A total of 
12 pediatric patients with -thalassemia received T 
and  B  cell  depleted  transplants  from  their 
haploidentical mothers with a median number of 15 
x 10
6 CD34 stem cells. To analyse the mechanisms 
involved  in  immunological  reconstitution  post 
transplant,  we  analysed  T  cell  subsets  by  flow 
cytometry,  particularly  NK  sets  (CD3-CD56+, 
CD3-CD16+ and CD56+CD16+ NK cells) at day + Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
20  and  +  60  post  transplant.  Day  +  20  post 
transplant,  the  patients  had  significantly  lower 
CD4+  T  cells  in  comparison  to  the  controls, 
whereas CD8+ T cells numbers did not statistically 
differ between patients and controls. NK cells were 
among  the  first  lymphocytes  to  repopulate  the 
peripheral blood, and up to 70% of these cells were 
CD3-CD56+
bright cells.  Interestingly,  a  direct 
correlation  has  been  observed  between  the 
percentages  of  CD56+CD16+  NK  subset  and  the 
BM engraftment and in all the patients the origin of 
the  NK subsets was from the  mothers. Day + 60 
post  transplant  an  increase  in  the  percentages  of 
CD4+  T  cells,  naïve  CD4+  cells  and  in  thymic 
naïve  Th  cells  were  observed  [Isgrò  A.  et  al 
submitted]
The Sickle Cell Anemia (SCA): The SCA is one of 
the most common autosomal recessive disorders in 
the  world.  A  mutation  in  theglobin  gene  
substitutes valine for glutamic acid at position 6 in 
the –globin chain of haemoglobin A,  resulting in a 
hemoglobin called S.  Approximately 8 % of black 
Americans  are  heterozygous  for  -globin  gene 
mutated    and    has sickle cells  trait.    1  in  600  is 
homozygous and has sickle cell disease. 
40 In sub –
Saharn  Africa  an  estimated  40  to  60  %  of 
population is heterozygous and 1 to 4 child have the 
disease
41.  However this can become a world-wide
social and healthy problem because   the migration  
from  Africa  is  increased  during    the  last  years. 
Moreover  these  patients  can  have  many  acute 
events  as  vaso-occlusive  pain  crisis,  acute  chest 
syndrome,  caused  by  physical  and  adhesive 
entrapment of red cells containing Hemoglobin S in 
the  microcirculation.  With  increasing  age  renal 
failure,  stroke,  avascular  necrosis  of  bone,  and 
pulmonary hypertension  begin to appear. SCD is an 
increasing  healthy  problem  in  the  European 
countries.
Bone  Marrow  Transplantation  for  Sickle  Cell 
Disease: Currently, stem cell transplantation (SCT; 
from bone marrow, peripheral blood and umbilical 
cord  blood)  is  the  only  treatment  that  offers  an 
effective cure for SCD patients. Although the first 
BMT for SCD was carried out in 1984, currently 
approximately  250  affected  patients  received 
transplant,  a  far  lower  number  than  undertaken 
during the same period for thalassemia. There are 
some  barriers  to  widely  applying  SCT  for  SCD 
patients.  The  absence  of  HLA  -identical  sibling 
donor  is  the  major  obstacle  for  expanding  this 
curative  treatment    to  many  potential  candidates 
with this disease. In fact, in one study, only 14% of 
eligible patients, who had siblings HLA typed, had 
an HLA-identical donor. For this reason, alternative 
sources  of  hematopoietic  stem  cells,  such  as 
unrelated  donor  marrow  or  umbilical  cord  blood, 
are  needed.  The  higher  individual  variability  of 
disease  severity,  and  some  progress  of 
pharmacological  therapy  such  as  hydroxiurea 
treatment  are also reasons for the delay or refuse of 
SCT  by  physicians  and  their  patients.  Another 
important obstacle is that there are no universally 
accepted criteria to identify the subset of patients at 
higher  risk  for  early  death.  This  has  led  several 
groups to offer SCT to patients with a significant 
clinical  complication  of  SCD (stroke  or  recurrent 
painful  episodes).  In  all  these  studies  main 
indications  for  transplant  were  vasoocclusive 
complications such as stroke, recurrent episodes of 
acute chest syndrome and/or painful crisis. 
Rome Results in Sickle Cell Disease: Since 2004 
in   we have performed BMT on 7 patients  with 
SCD  in  our  center.  Patients  (median  age  of  13 
years; range 2-16 years)  received BU/CY/ATG  as 
conditioning  regimen  and  CSA+short  MTX  as 
GvHD prophylaxis.  All  patients  had  a  sustained 
engraftment. Six patients are alive and well while 1 
patient died at 1 year after BMT at home. (Table 3)
Table 3. BMT on 7 patients with SCA transplanted at the Roma 
Center.
Age, yrs F-up, mo Outcome
1
2
3
4
5
6
7
13
13
14
10
16
2
12
24
16
12
10
12
6
1,5
alive & cured
alive & cured
alive & cured
alive & cured
Died at home
alive & cured
alive &cured
Conclusions: Hematopoietic cell transplantation is 
the  only  treatment  able  to  definitively  cure 
thalassemia and sickle cell disease.  Class 1 patients 
with thalassemia  have a very high probability of 
cure with a very low early and late morbidity and 
mortality. Therefore there is no reason to deny these 
patients  the  advantages  of  a  life  free  from  daily 
tedious, expensive and uncomfortable therapy. We 
still  do  not  know  the  probability  that  a  patient Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
receiving conventional therapy will deteriorate into 
a worse risk category, but the fact is that transplant 
centers  are  often  confronted  with  patients  in  risk 
classes  2  and  3  who  represent  failures  of 
conventional  treatment.  Delaying  transplantation 
until the patient is in a risk category beyond class 1 
substantially  reduces  the  probability  of  transplant 
success and jeopardizes the reversibility of liver and 
cardiac  damage.  We  therefore  believe  that  all 
patients  with  -thalassemia  who  have  HLA-
identical  related donors  should  be  transplanted as 
soon as possible. 
Patients  without  such  donors  who  have  well-
selected unrelated donors should also be considered 
for HCT. Our recent results suggest that maternal 
haploidentical  HSCT  is  feasible  for  patients  with 
thalassemia  who  lack  a  matched  related  and 
unrelated  donor. The  Rome  experience  confirmed 
the  results  obtained  in  Pesaro,  and  most 
importantly,  showed  the  reproducibility  of  the 
Pesaro  experience  in  other  centers  and  with  the 
patients ethnically  heterogeneous.
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